Ameriprise Financial Inc. reduced its position in shares of Glaukos Corporation (NYSE:GKOS) by 1.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 101,905 shares of the medical instruments supplier’s stock after selling 1,602 shares during the period. Ameriprise Financial Inc. owned approximately 0.30% of Glaukos worth $3,361,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in GKOS. Ameritas Investment Partners Inc. lifted its holdings in Glaukos by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,212 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Glaukos by 740.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 3,118 shares during the last quarter. Quantbot Technologies LP lifted its holdings in Glaukos by 291.3% during the 3rd quarter. Quantbot Technologies LP now owns 7,653 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 5,697 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Glaukos during the 2nd quarter worth approximately $262,000. Finally, UBS Asset Management Americas Inc. acquired a new stake in Glaukos during the 2nd quarter worth approximately $274,000. 99.23% of the stock is owned by institutional investors and hedge funds.
In related news, CFO Joseph E. Gilliam acquired 2,100 shares of the stock in a transaction on Wednesday, November 22nd. The shares were purchased at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the purchase, the chief financial officer now directly owns 102,100 shares in the company, valued at $2,434,064. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 16.40% of the stock is owned by company insiders.
Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.06. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. The firm had revenue of $40.41 million for the quarter, compared to analyst estimates of $38.69 million. During the same quarter last year, the company earned $0.03 EPS. The company’s revenue was up 36.6% on a year-over-year basis.
Several research firms recently weighed in on GKOS. BidaskClub raised Glaukos from a “hold” rating to a “buy” rating in a report on Tuesday, September 12th. Cantor Fitzgerald reissued a “buy” rating and set a $60.00 price target (up from $54.00) on shares of Glaukos in a report on Thursday, September 14th. Stephens reissued a “buy” rating and set a $47.00 price target on shares of Glaukos in a report on Friday, September 15th. Piper Jaffray Companies reissued a “buy” rating and set a $38.00 price target on shares of Glaukos in a report on Friday, September 15th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Glaukos in a report on Thursday, September 14th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $44.86.
ILLEGAL ACTIVITY NOTICE: “Ameriprise Financial Inc. Reduces Position in Glaukos Corporation (GKOS)” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.chaffeybreeze.com/2018/01/04/ameriprise-financial-inc-reduces-position-in-glaukos-corporation-gkos.html.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.